Zacks Research Issues Pessimistic Forecast for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research dropped their Q4 2025 earnings estimates for Teva Pharmaceutical Industries in a report released on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.66 for the quarter, down from their previous forecast of $0.75. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.77 EPS, Q4 2026 earnings at $0.68 EPS and FY2027 earnings at $2.73 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

A number of other analysts have also recently issued reports on TEVA. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $15.32 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $17.37 billion, a PE ratio of -10.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The company has a 50 day moving average price of $19.00 and a two-hundred day moving average price of $18.40. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stifel Financial Corp increased its stake in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $24,314,000. Finally, Pinnbrook Capital Management LP acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $4,966,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.